Keio University · Faculty of Pharmaceutical Sciences / Graduate School of Pharmaceutical Sciences · 助教

Research keywordsmultiple myeloma・therapy resistance・epigenetic regulation・splicing factor inhibition・EZH2 signaling・DNMT1 stabilization

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Multifaceted MRVI1 Serves as a Tumor 1 Suppressor in HCT116 Colorectal Cancer Cells.2026 · Biol Pharm Bull. in press 2026年02月
• Identification of a CD138-negative therapy-resistant subpopulation in multiple myeloma with vulnerability to splicing factor inhibition.2025 · Blood cancer discovery 2025年09月
• Identification of MRVI1-Interacting Proteins by Biotin-Based Proximity Labeling Reveals NPM-ALK-Dependent Interaction Dynamics.2025 · J Biochem. 2025, Dec 2;178(6):415-434 2025年10月
• Targeting a therapy-resistant subpopulation with vulnerability to splicing pathway inhibition in multiple myeloma.2025 · Blood Cancer Discov. 2025, Nov 3;6(6):602-622 2025年09月

• EZH2機能喪失を伴う骨髄異形成症候群のがん幹細胞維持機構の解明と創薬標的分子の探索2025 · -
• 新規複合体「PRC1-PRC2複合体」の解析2025 · -
• EZH2機能喪失型骨髄異形成症候群に対する創薬標的分子の探索2024 · -
• "残存H3K27me3"を標的とするEZH2 機能低下型MDS に対する創薬研究2024 · -